Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

LY96 Antikörper

LY96 Reaktivität: Human FACS, InhA Wirt: Maus Monoclonal 18H10 unconjugated
Produktnummer ABIN2192085
  • Target Alle LY96 Antikörper anzeigen
    LY96 (Lymphocyte Antigen 96 (LY96))
    Reaktivität
    • 55
    • 12
    • 5
    • 2
    • 1
    • 1
    • 1
    • 1
    Human
    Wirt
    • 41
    • 18
    Maus
    Klonalität
    • 44
    • 15
    Monoklonal
    Konjugat
    • 28
    • 10
    • 8
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser LY96 Antikörper ist unkonjugiert
    Applikation
    • 42
    • 22
    • 8
    • 8
    • 7
    • 4
    • 4
    • 4
    • 3
    • 3
    • 3
    • 1
    • 1
    • 1
    Flow Cytometry (FACS), Inhibition Assay (InhA)
    Sterilität
    0.2 μm filtered
    Immunogen
    TLR4/MD-2 expressing CHO cells/ chimeric TLR4/MD-2 fusion protein
    Klon
    18H10
    Top Product
    Discover our top product LY96 Primärantikörper
  • Applikationshinweise
    For flow cytometry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, dilutions have to be made according to the amounts of MD-2 to be inactivated.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Buffer
    PBS, containing 0.1 % bovine serum albumin.
    Lagerung
    4 °C
    Informationen zur Lagerung
    Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.
    Haltbarkeit
    12 months
  • Tissières, Dunn-Siegrist, Schäppi, Elson, Comte, Nobre, Pugin: "Soluble MD-2 is an acute-phase protein and an opsonin for Gram-negative bacteria." in: Blood, Vol. 111, Issue 4, pp. 2122-31, (2008) (PubMed).

    Daubeuf, Mathison, Spiller, Hugues, Herren, Ferlin, Kosco-Vilbois, Wagner, Kirschning, Ulevitch, Elson: "TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 179, Issue 9, pp. 6107-14, (2007) (PubMed).

    Elson, Dunn-Siegrist, Daubeuf, Pugin: "Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria." in: Blood, Vol. 109, Issue 4, pp. 1574-83, (2007) (PubMed).

    Pugin, Stern-Voeffray, Daubeuf, Matthay, Elson, Dunn-Siegrist: "Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock." in: Blood, Vol. 104, Issue 13, pp. 4071-9, (2004) (PubMed).

  • Target
    LY96 (Lymphocyte Antigen 96 (LY96))
    Andere Bezeichnung
    Md-2 (LY96 Produkte)
    Synonyme
    MD2 antikoerper, ESOP-1 antikoerper, MD-2 antikoerper, ly-96 antikoerper, Ly-96 antikoerper, Md2 antikoerper, lymphocyte antigen 96 antikoerper, LY96 antikoerper, Ly96 antikoerper
    Hintergrund
    The monoclonal antibody 18H10 reacts with MD-2, an accessory molecule of the Toll-like receptor 4 (TLR4, CD284). TLRs belong to a family of proteins that specifically recognizes and senses microbial products. They are highly conserved throughout evolution and act as innate immune recognition receptors against many pathogens. TLR4 is a functional receptor for gram-negative bacterial lipopolysaccharides (LPS). TLR4 associates with MD-2 which is absolutely required for LPS-induced activation of TLR4. MD-2 exists as a cell surface protein in association with TLR4. It also exists as secreted forms consisting of MD-2 monomers and multimers (sMD-2). Circulating sMD-2 is mainly present as a doublet of ~20 and 25 kD, representing differentially glycosylated forms. Unlike TLR4, sMD-2 binds directly LPS without the need of soluble CD14 (sCD14). However, LPS-MD-2 interactions are increased when LPS is pretreated with CD14. Only monomeric sMD-2 is biologically active and able to associate with TLR4 and LPS. sMD-2 circulates in plasma of healthy individuals as a non-active, polymeric protein. In septic plasma, the total amount of sMD-2 was strongly elevated and contained both sMD-2 polymers and monomers. Soluble MD-2 is proposed to be an important mediator of organ inflammation during sepsis. During experimental human endotoxemia, the monomeric and total sMD-2 content in plasma increased with the kinetics of an acute phase protein. This parallels enhanced TLR4 costimulatory activity. In vitro studies revealed that sMD-2 release appears to be restricted to endothelial and dendritic cells. The monoclonal antibody 18H10 reacts with MD-2. However, it does not react with sMD-2. In addition, the monoclonal antibody 18H10 is able to inhibit bacterial binding to MD-2. Aliases Lymphocyte antigen 96, ESOP-1, LY96
    Pathways
    TLR Signalweg, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Toll-Like Receptors Cascades
Sie sind hier:
Kundenservice